Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
In RCT (n=557, first-line treatment with osimertinib plus chemotherapy led to significantly longer progression-free (PF) survival than osimertinib monotherapy (HR disease progression/death, 0.62;95% CI, 0.49-0.79; p<0.001). At 24 months, 57% vs 41%, respectively, were alive & PF.
Source:
New England Journal of Medicine
SPS commentary:
An editorial notes that many questions remain about combined therapy, but this study takes a great leap with its findings, and though not yet considered to be standard therapy, it suggests it will be a treatment option, especially for brain metastasis in EGFR-mutated lung cancer.